Details

Autor(en) / Beteiligte

• Ye, Ziyu
• Liang, Yanfang
• Yan
• Lin, Bihua
• Cao, Longbin
• Wang, Bin
• Zhang, Zhao
• Yu, Haibo
• Li, Jixia
• Huang, Mingyuan
• Zhou, Keyuan
• Zhang, Qunzhou
• Liu, Xinguang
• Zeng, Jincheng

Titel

Targeted photodynamic therapy of cancer using a novel gallium corrole conjugated-mAb directed against cancer/testis antigens 83

Ist Teil von

• Cancer medicine (Malden, MA), 2018-06, Vol.7 (7), p.3057

Ort / Verlag

John Wiley & Sons, Inc

Erscheinungsjahr

2018

Quelle

Wiley Journals

Beschreibungen/Notizen

• Photodynamic therapy (PDT) is a noninvasive, highly selective approach to the treatment of tumors. However, its therapeutic effect is limited by long-lasting skin phototoxicity. Therefore, to compromise this shortcoming, it is preferable to deliver photosensitizers selectively to tumor cells with the aid of antibodies specific against tumor-associated antigens. Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. Herein, we developed and characterized a novel mouse CT83 mAb 7G4 with a high affinity with Gallium (III) 5, 10, 15-tris (ethoxycarbonyl) corrole (1-Ga), a new and promising photosensitizer in PDT. The enzyme-linked immunosorbent assay (ELISA), flow cytometry and cytotoxicity activity assays revealed that 7G4-1-Ga was able to recognize human CT83 with high specificity. Furthermore, 7G4-1-Ga showed greater cytotoxicity to CT83-expressing human cancer cells in vitro than 1-Ga. These results suggest that the antibody-conjugated photosensitizer between anti-CT83 mAb and 1-Ga may have a good application in PDT, where the destruction of CT83-expressing tumor is required.